Induced Pluripotent Stem Cells Market Size was valued at USD 1.4 Billion in 2022. The Induced Pluripotent Stem Cells market industry is projected to grow from USD 1.5 Billion in 2023 to USD 3.4 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.50% during the forecast period (2024 - 2032).
The rising prevalence of chronic diseases is one of the key market drivers enhancing market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for Induced Pluripotent Stem Cells is being driven by the rising prevalence of chronic diseases, such as cancer, neurodegenerative disorders, cardiovascular diseases, and diabetes. iPSCs offer unique opportunities for disease modeling, drug screening, and personalized medicine due to their ability to differentiate into various cell types relevant to these conditions. By recapitulating disease phenotypes in vitro, iPSC-based models enable researchers to study disease mechanisms, identify therapeutic targets, and screen potential drug candidates more accurately.
Moreover, iPSC-derived cell therapies hold promise for regenerating damaged tissues and organs, offering potential treatments for chronic diseases with unmet medical needs. As the burden of chronic diseases continues to escalate globally, the demand for iPSC-based research and therapeutic solutions.
The growing demand for cell therapy is a significant driver of the Induced Pluripotent Stem Cells (iPSCs) Market. iPSCs serve as a valuable source for generating a wide variety of cell types suitable for therapeutic applications, including cardiomyocytes, neurons, hepatocytes, and pancreatic beta cells. These iPSC-derived cells offer potential treatments for a range of diseases and injuries, including cardiovascular disorders, neurodegenerative diseases, liver diseases, and diabetes.
With increasing recognition of the limitations of traditional treatment modalities and the potential of cell-based therapies to address unmet medical needs, there is a rising demand for iPSC-derived cell products. Moreover, advancements in iPSC technology, such as improved differentiation protocols and genome editing tools, enhance the feasibility and efficacy of iPSC-based cell therapies, further driving market growth in the field.
Strategic collaborations and partnerships play a crucial role in driving the Induced Pluripotent Stem Cells (iPSCs) Market by facilitating knowledge exchange, technology transfer, and joint initiatives. These collaborations bring together expertise from academia, industry, and research institutions, enabling the development of innovative iPSC-based products and therapies. By pooling resources and sharing infrastructure, collaborators can accelerate iPSC research and commercialization, overcoming technical challenges and reducing development timelines.
Moreover, partnerships between iPSC technology providers and pharmaceutical companies foster the translation of iPSC-derived therapies from bench to bedside, leveraging industry expertise and regulatory insights. Strategic alliances also enable access to complementary technologies, expanded market reach, and diversified revenue streams, enhancing the competitiveness and sustainability of iPSC-focused companies in the dynamic healthcare landscape. Thus, driving the Induced Pluripotent Stem Cells market revenue.
For instance, the Prepaire Labs has entered into a five-year partnership with Ncardia to expedite drug discovery and development processes, encompassing target discovery, lead optimization, toxicity assessment, and trial design. This collaboration aims to advance iPSC development by reprogramming adult cells, such as skin and blood cells, into an embryonic stem cell-like state capable of differentiating into various human cell types.
The Induced Pluripotent Stem Cells Market segmentation, based on derived cell type, includes Hepatocytes, Fibroblasts, Keratinocytes, Neurons and Others. In 2023, the Hepatocytes segment dominated the market, accounting for 35% of market revenue due to its pivotal role in liver disease modeling, drug metabolism studies, and regenerative medicine applications. Hepatocytes derived from iPSCs offer a scalable and physiologically relevant cell source for liver cell therapy and drug screening, addressing the demand for innovative treatments for liver diseases and improving preclinical drug development outcomes. Hepatocytes derived cell type holds the largest market share in the iPSCs Market.
Fibroblasts derived cell type is experiencing the highest Compound Annual Growth Rate (CAGR) in the Induced Pluripotent Stem Cells (iPSCs) Market due to its versatility and wide-ranging applications. These cells serve as a foundational source for generating diverse cell types, making them valuable for disease modeling, drug screening, and regenerative medicine. Additionally, advancements in reprogramming technologies and differentiation protocols enhance the efficiency and scalability of fibroblast-derived iPSCs, driving their increased adoption and market growth across various therapeutic areas.
The Induced Pluripotent Stem Cells Market segmentation, based on application, includes Drug Development, Regenerative Medicine, Toxicity Testing, Tissue Engineering and Cell Therapy.
In 2023, the Drug Development category generated the most income due to the critical role iPSCs play in accelerating drug discovery and development processes. iPSCs serve as valuable tools for disease modeling, toxicity testing, and drug screening, offering physiologically relevant cellular models for studying disease mechanisms and evaluating drug efficacy and safety. Additionally, iPSC-based platforms enable high-throughput screening of potential drug candidates and personalized medicine approaches, driving their widespread adoption in pharmaceutical research and development and solidifying their position as market leaders in the iPSCs Market.
The Regenerative Medicine application is experiencing the highest Compound Annual Growth Rate (CAGR) in the Induced Pluripotent Stem Cells (iPSCs) Market due to its transformative potential in addressing unmet medical needs. iPSCs offer a scalable and patient-specific cell source for tissue regeneration and organ repair, holding promise for treating various diseases and injuries. With ongoing advancements in iPSC technology and increasing investment in regenerative medicine research, the demand for iPSC-based therapies continues to grow, driving market expansion in the Regenerative Medicine application segment.
Figure 1: Induced Pluripotent Stem Cells Market, by Application, 2023 & 2032(USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Induced Pluripotent Stem Cells Market segmentation, based on end user, includes Research Institutions and Other End Users. In 2023, the research institutions category generated the most income due to its pivotal role in advancing iPSC research and technology. Research institutions serve as hubs for innovative research initiatives, driving the development of iPSC-based applications in disease modeling, drug discovery, and regenerative medicine. Additionally, these institutions have access to funding, expertise, and infrastructure necessary for iPSC research, enabling them to lead the way in exploring new avenues and applications for iPSCs and maintaining their largest market share.
By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Induced Pluripotent Stem Cells market area will dominate this market as it boasts a robust healthcare infrastructure. North America leads the Induced Pluripotent Stem Cells (iPSCs) Market due to several factors. It boasts a robust healthcare infrastructure, significant investments in biomedical research, and a large presence of key market players. Additionally, favorable regulatory policies and government initiatives support iPSC research and commercialization. Moreover, the region's strong focus on innovative technologies and personalized medicine drives the adoption of iPSC-based applications in drug discovery, regenerative medicine, and disease modeling, solidifying its position as the largest market for iPSCs.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: INDUCED PLURIPOTENT STEM CELLS MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Induced Pluripotent Stem Cells market accounts for the second-largest market share due to the strong regulatory frameworks supporting iPSC research and development. Europe holds the second-largest share in the Induced Pluripotent Stem Cells (iPSCs) Market due to its well-established healthcare infrastructure, significant investments in life sciences research, and strong regulatory frameworks supporting iPSC research and development. Moreover, Europe fosters collaborations between academia, industry, and government, driving innovation and technology transfer in iPSC-based applications. Additionally, the region's focus on personalized medicine and regenerative therapies contributes to the adoption of iPSCs in clinical and research settings, securing its position as a key player in the iPSCs Market. Further, the German Induced Pluripotent Stem Cells market held the largest market share, and the UK Induced Pluripotent Stem Cells market was the fastest growing market in the European region.
The Asia-Pacific Induced Pluripotent Stem Cells Market is expected to grow at the fastest CAGR from 2024 to 2032. The Asia Pacific region experiences the highest Compound Annual Growth Rate (CAGR) in the Induced Pluripotent Stem Cells (iPSCs) Market due to several factors. These include increasing investments in healthcare infrastructure, rising research and development activities, and a growing prevalence of chronic diseases. Additionally, expanding collaborations between academia, industry, and government drive innovation and adoption of iPSC-based technologies. With a large and aging population, coupled with rising healthcare expenditures and demand for advanced diagnostics and therapeutics, Asia Pacific presents significant growth opportunities in the iPSCs Market. Moreover, China’s Induced Pluripotent Stem Cells market held the largest market share, and the Indian Induced Pluripotent Stem Cells market was the fastest growing market in the Asia-Pacific region.
Leading players in the Induced Pluripotent Stem Cells (iPSCs) Market, including Thermo Fisher Scientific, Merck KGaA, and Fujifilm Cellular Dynamics, are focusing on expanding their product portfolios and enhancing their technological capabilities. These companies are investing in research and market developments initiatives to develop innovative iPSC-based products and services for drug discovery, regenerative medicine, and disease modeling. Additionally, strategic collaborations and partnerships enable these players to strengthen their market presence and address emerging opportunities in the dynamic iPSCs Market landscape.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Induced Pluripotent Stem Cells industry to benefit clients and increase the market sector. In recent years, the Induced Pluripotent Stem Cells industry has offered some of the most significant advantages to drug development. Major players in the Induced Pluripotent Stem Cells market, including Thermo Fisher Scientific, Inc., Merck KGaA, Fujifilm Cellular Dynamics International, ReproCELL Inc., Takara Bio Inc., Lonza Group AG, Stemgent, Fate Therapeutics, Inc., Astellas Pharma Inc., Bristol Myers Squibb and others, are attempting to increase market demand by investing in research and development operations.
Thermo Fisher Scientific, Inc. is a leading player in the Induced Pluripotent Stem Cells (iPSCs) Market, offering a comprehensive portfolio of products and services for iPSC research and applications. The company provides a wide range of reagents, media, and kits for iPSC culture, maintenance, and differentiation, enabling researchers to generate and manipulate iPSCs efficiently. Thermo Fisher Scientific also offers advanced instruments and platforms for iPSC characterization, genome editing, and functional analysis. Moreover, the company provides custom services, including iPSC generation, genome editing, and disease modeling, catering to the diverse needs of academic, biotechnology, and pharmaceutical customers. With its extensive expertise and innovative solutions, Thermo Fisher Scientific continues to drive advancements in iPSC research and technology, empowering scientists to unlock new insights into human biology and disease.
Takara Bio Inc. is a prominent player in the Induced Pluripotent Stem Cells (iPSCs) Market, offering innovative solutions for iPSC research and applications. The company provides a comprehensive range of products, including reagents, kits, and instruments, designed to support iPSC culture, differentiation, and analysis. Takara Bio's iPSC-related offerings encompass cell culture media, reprogramming factors, genome editing tools, and iPSC characterization assays, catering to the diverse needs of researchers in academia, biotechnology, and pharmaceutical industries. Additionally, Takara Bio offers custom services for iPSC generation, genome editing, and disease modeling, empowering researchers to advance their iPSC-based research initiatives. With its commitment to innovation and quality, Takara Bio continues to drive advancements in iPSC technology, enabling breakthroughs in regenerative medicine, drug discovery, and disease modeling.
October 2022: CiRA Foundation and the Cell and Gene Therapy Catapult (CGT Catapult) have jointly initiated a new collaborative research endeavor focusing on induced pluripotent stem (iPS) cell characterization. The aim of this initiative is to foster the utilization of iPS cell technologies in advancing products for regenerative medicine.
April 2022: TreeFrog Therapeutics introduced The Stem Cell SpaceShot Grant, providing USD 100,000 in research funding for advancements in the realm of stem cell biology and regenerative medicine.
| Report Attribute/Metric | Details |
| Market Size | USD 3.4 Billion (By 2032) |
| Compound Annual Growth Rate (CAGR) | 10.50% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Derived Cell Type, Application, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Â Thermo Fisher Scientific, Inc., Merck KGaA, Fujifilm Cellular Dynamics International, ReproCELL Inc., Takara Bio Inc., Lonza Group AG, Stemgent, Fate Therapeutics, Inc., Astellas Pharma Inc. and Bristol Myers Squibb |
| Key Market Opportunities | ·        Regenerative Medicine and Drug Discovery and Development |
| Key Market Dynamics | ·        Rising Prevalence of Chronic Diseases and Growing Demand for Cell Therapy |
Frequently Asked Questions (FAQ) :
The Induced Pluripotent Stem Cells Market size was valued at USD 1.5 Billion in 2023.
The global market is projected to grow at a CAGR of 10.50% during the forecast period, 2024-2032.
North America had the largest share in the global market
The key players in the market are Thermo Fisher Scientific, Inc., Merck KGaA, Fujifilm Cellular Dynamics International, ReproCELL Inc., Takara Bio Inc., Lonza Group AG, Stemgent, Fate Therapeutics, Inc., Astellas Pharma Inc. and Bristol Myers Squibb Company.
The drug development category dominated the market in 2023.
The Research Institutions category had the largest share in the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
